July 10 (Reuters) - Takeda Pharmaceutical Co Ltd 4502.T :
* HEALTH CANADA HAS AUTHORIZED VYVANSE® (LISDEXAMFETAMINE DIMESYLATE), THE FIRST AND ONLY, CHEWABLE TABLET FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD)1*
* TAKEDA CANADA - HEALTH CANADA HAS AUTHORIZED A CHEWABLE TABLET OF VYVANSE
* TAKEDA CANADA - VYVANSE CHEWABLE TABLETS ARE INDICATED FOR TREATMENT OF MODERATE TO SEVERE BINGE EATING DISORDER IN ADULTS AGED 18 AND OLDER
* TAKEDA CANADA - VYVANSE CHEWABLE TABLETS ARE EXPECTED TO BE AVAILABLE IN FALL 2019.